Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Year: 2019
Type: article
Abstract: The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42 ), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181 ) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ 42 to Aβ 40 (Aβ 42/40 Ratio) has been suggested to be superior to the concentration of Aβ 42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ 42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ 42/40 ratio, rather than the absolute value of CSF Aβ 42 , should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.
Source: Alzheimer s Research & Therapy
Institutions: Lund University, Skåne University Hospital, Inserm, Université de Montpellier, Universität Ulm, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, University of Gothenburg, Medical University of Białystok, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,580
OpenAlex ID: W2945980668
